Decnupaz (pivekimab sunirine-pvzy) Coverage Criteria
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0304 alerts
Get alerted when Policy CC-0304 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical-benefit coverage and prior authorization review for Decnupaz (pivekimab sunirine-pvzy). Coverage may be approved for individuals younger than 19 years or for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN); other indications are not approved.
HCPCS code C9399 was removed from the policy effective September 30, 2026.
HCPCS code C9313 was added effective October 1, 2026 for injection of pivekimab sunirine-pvzy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.